Key Highlights
- A leading med-tech company reported first quarter Revenue of $9.8 billion, up 13.7% both as reported and organically, and raised its full-year organic revenue growth guidance to a range of 7.25% to 7.75%.
- The company announced a roughly $700 million Partnership with a robotics firm to distribute a new surgical system outside the US, complementing its existing flagship robotic-assisted surgery platform.
- A separate strategic Investment of up to $80 million was disclosed in a structural heart technology company, with an option to acquire it for an estimated upfront price of up to $210 million upon meeting certain milestones.
- Cardiovascular revenue grew 18.9% organically, led by 29.1% growth in Electrophysiology Therapies, while the company also raised its non-GAAP Diluted Earnings per Share guidance to $5.94 to $6.00.
A Strong Start to the Fiscal Year
Medtronic (NYSE:MDT) reported first quarter fiscal 2027 revenue of $9.8 billion, an increase of 13.7% both as reported and on an organic basis, coming in roughly 200 basis points above the midpoint of the company's own guidance. The healthcare technology company posted GAAP diluted earnings per share of $1.14 and non-GAAP diluted earnings per share of $1.45, both ahead of expectations.
Growth was broad-based across the company's major Business lines. Cardiovascular revenue grew 18.9% on an organic basis, driven by 29.1% growth in Electrophysiology Therapies and continued strength in Cardiac Ablation Solutions. Neuroscience revenue increased 9.3% organically, supported by growth in Cranial and Spinal Technologies, while Medical Surgical revenue rose 10.2% organically on strength in Surgical and Endoscopy as well as Acute Care and Monitoring. The company's chief executive said the breadth of performance across its businesses, along with increasing contributions from newer growth platforms, gives the company confidence in its execution and Long-term Growth trajectory.
Guidance Raised on Strength Across the Portfolio
Following the results, the company raised its fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75%, up from its prior guidance of 6.75% to 7.25%. It also lifted its full-year non-GAAP diluted earnings per share guidance to a range of $5.94 to $6.00, up from the previous range of $5.90 to $6.00. The chief financial officer said the combination of strong operating performance and disciplined financial management drove results ahead of expectations, enabling the higher outlook for the remainder of the fiscal year.
The quarter's results were aided by an extra fiscal week that fell within the reporting period, which the company estimated contributed approximately $570 million to organic growth. The period also included revenue from two recently closed acquisitions, a vascular device maker and a peripheral nerve stimulation company, which closed in June and July respectively.
Robotics Portfolio Expands With New Partnership
Alongside its earnings, the company announced a strategic partnership with a surgical robotics firm valued at approximately $700 million, giving it rights to distribute the firm's new surgical system in select markets outside the US where the system has received regulatory approval. The new system is expected to complement the company's existing robotic-assisted surgery platform rather than replace it, giving surgeons and health systems a broader choice of robotic platforms.
A senior vice president overseeing the company's surgical business said the strategy is focused on driving the next generation of minimally invasive surgery, and that the addition of the new platform alongside its existing system will make the company the only one offering a two-platform robotic portfolio combined with its broader surgical ecosystem. The company's existing robotic system is currently used in more than 35 countries across six continents, including the US, where it received regulatory clearance within the past year, with procedure growth currently running at more than twice the pace of the broader robotic surgery market. The partner firm's new system has completed multi-specialty Clinical Trials and received a CE Mark in May for use in general, gynecologic, thoracic, and urologic procedures, in addition to existing approvals in China and Singapore.
A Second Deal Targets Complex Heart Valve Procedures
The company also announced a separate strategic investment in a structural heart technology firm focused on leaflet modification for structural heart disease. Under the agreement, it will invest up to $80 million in the company and is expected to become the exclusive global commercial distributor of its leaflet modification device beginning in 2027. The agreement also includes an option to acquire the company outright upon achievement of predefined milestones, at an estimated upfront price of up to $210 million, with additional earn-out payments that could increase the total consideration further.
The device in question is a regulatory-cleared leaflet modification technology designed to enable valve-in-valve procedures in patients at risk of coronary obstruction during transcatheter aortic valve replacement. A vice president overseeing the structural heart business said the investment reflects a commitment to building a portfolio of technologies aimed at addressing increasingly complex TAVR cases, adding that leaflet modification tools have the potential to become a standard part of structural heart care as transcatheter therapies continue to advance.
A Day of Announcements Reinforcing Broader Strategy
Together, the three announcements reflect a continued push to combine steady core financial performance with targeted investment in emerging surgical and structural heart technologies. The company also continues to work through the planned separation of its diabetes business, which it expects to complete through a series of Capital Markets transactions, with a split-off currently viewed as the preferred structure, though a final decision has not yet been made. With guidance raised and two new technology partnerships added to its pipeline in the same reporting period, near-term focus is likely to center on integrating the new platforms while sustaining the broad-based growth reflected in the first quarter results.






Please wait processing your request...